Varenicline-induced drug eruption with resulting palmar/plantar hyperhidrosis and dysesthesia

Journal of the American Academy of Dermatology

Volumn 63, Issue 1, 2010, Pages

  Nicholas, Matilda W ^a   Isenstein, Arin ^a   Dasher, David ^a   Granko, Robert P ^b   Lugo Somolinos, Aida ^a   Groben, Pamela ^a   Morrell, Dean S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHINYLESTRADIOL; IMIQUIMOD; NORGESTIMATE; PREDNISONE; VARENICLINE;

ADULT; ARTICLE; BURNING SENSATION; CASE REPORT; CONDYLOMA ACUMINATUM; DRUG ERUPTION; DRUG WITHDRAWAL; DYSESTHESIA; FEMALE; HUMAN; HYPERHIDROSIS; NICOTINE REPLACEMENT THERAPY; PHYSICAL EXAMINATION; PLANTAR HYPERHIDROSIS; PRIORITY JOURNAL; PRURITUS; SMOKING CESSATION; TOBACCO DEPENDENCE;

ADULT; BENZAZEPINES; DRUG ERUPTIONS; FEMALE; FOOT; GLUCOCORTICOIDS; HAND; HUMANS; HYPERHIDROSIS; NICOTINIC AGONISTS; PARESTHESIA; PREDNISOLONE; QUINOXALINES;

EID: 77953236777     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.04.037     Document Type: Article

References (10)

1. Jorenby D.E., Hays J.T., Rigotti N.A., Azoulay S., Watsky E.J., Williams K.J., et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296 (2006) 56-63
2. Gonzales D., Rennard S.I., Nides M., Oncken C., Azoulay S., Billing C.B., et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296 (2006) 47-55
3. Tonstad S., Tønnesen P., Hajek P., Williams K.E., Billing C.B., Reeves K.R., et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 296 (2006) 64-71
4. Pirmoradi P., Roshan S., and Nadeem S.S. Neuropsychiatric disturbance after initiation of varenicline in a patient with a history of alcohol abuse and major depression. Am J Health Syst Pharm 65 (2008) 1624-1626
5. Kuehn B.M. FDA warns of adverse events linked to smoking cessation drug and antiepileptics. JAMA 299 (2008) 1121-1122
6. Song W., and Miller W.A. Diffuse exanthema in a patient receiving varenicline. Am J Health Syst Pharm 65 (2008) 1239-1241
7. Mihalak K.B., Carroll F.I., and Luetje C.W. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol 70 (2006) 801-805
8. Kurzen H., Berger H., Jäger C., Hartschuh W., Näher H., Gratchev A., et al. Phenotypical and molecular profiling of the extraneuronal cholinergic system of the skin. J Invest Dermatol 123 (2004) 937-949
9. Naranjo C.A., Busto U., Sellers E.M., Sandor P., Ruiz I., Roberts E.A., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30 (1981) 239-245
10. Thompson G.H., and Hunter D.A. Nicotine replacement therapy. Ann Pharmacother 32 (1998) 1067-1075